PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma
- First Posted Date
- 2019-03-18
- Last Posted Date
- 2023-04-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT03878719
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Lombardy, Italy
Acute Treatment Trial in Adult Subjects With Migraines
- Conditions
- Migraine
- Interventions
- First Posted Date
- 2019-03-13
- Last Posted Date
- 2023-09-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 2154
- Registration Number
- NCT03872453
- Locations
- 🇺🇸
CT Clinical Research, Cromwell, Connecticut, United States
🇺🇸Elite Clinical Studies, Phoenix, Arizona, United States
🇺🇸Optimus Medical Group, San Francisco, California, United States
OPEN LABEL, 2-PERIOD STUDY, TO COMPARE BIO-AVAILABILITY OF 2 DIFFERENT FORMULATIONS OF PF-05221304 IN HEALTHY ADULTS
- Conditions
- Healthy
- Interventions
- Drug: PF-05221304 Formulation BDrug: PF-05221304 Formulation A
- First Posted Date
- 2019-03-12
- Last Posted Date
- 2020-05-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 10
- Registration Number
- NCT03871439
- Locations
- 🇺🇸
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States
Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors
- Conditions
- Metastatic MelanomaAdvanced Solid Tumors
- Interventions
- First Posted Date
- 2019-03-06
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 56
- Registration Number
- NCT03864042
- Locations
- 🇨🇦
Sir Mortimer B Davis Jewish General Hospital, Montreal, Quebec, Canada
🇺🇸UC Irvine Health, Orange, California, United States
🇺🇸University of Colorado Hospital - Anschutz Cancer Pavilion (ACP), Aurora, Colorado, United States
Evaluate Severe Hepatic Impairment on Dacomitinib PK
- First Posted Date
- 2019-03-06
- Last Posted Date
- 2020-11-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT03865446
- Locations
- 🇺🇸
Investigational Drug Services (IDS) University of Miami Hospitals and Clinics, Research Pharmacy, Miami, Florida, United States
🇺🇸University of Miami Division of Clinical Pharmacology, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
Study Evaluating the Effects of PSI-697 on Platelets in Subjects Who Smoke
- First Posted Date
- 2019-03-04
- Last Posted Date
- 2019-03-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 30
- Registration Number
- NCT03860506
A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B
- Conditions
- Hemophilia B
- Interventions
- Biological: PF-06838435/ fidanacogene elaparvovec
- First Posted Date
- 2019-03-04
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 51
- Registration Number
- NCT03861273
- Locations
- 🇸🇦
King Abdulaziz Medical City-Ministry of national guard, Riyadh, Kingdom OF Saudi Arabia, Saudi Arabia
🇺🇸University of California, San Francisco - Clinical Research Center, San Francisco, California, United States
🇺🇸University of California, San Francisco - Outpatient Hematology Clinic, San Francisco, California, United States
A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors
- Conditions
- Metastatic Solid TumorsAdvanced Solid Tumors
- Interventions
- Drug: PF-06939999 dose escalationDrug: PF-06939999 monotherapyDrug: PF-06939999 in combination with docetaxel
- First Posted Date
- 2019-02-26
- Last Posted Date
- 2022-11-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 54
- Registration Number
- NCT03854227
- Locations
- 🇺🇸
Scottsdale Healthcare Hospitals d/b/a HonorHealth, Scottsdale, Arizona, United States
🇺🇸Virginia G. Piper Cancer Pharmacy, Scottsdale, Arizona, United States
🇺🇸Keck Hospital of USC, Los Angeles, California, United States
Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis
- First Posted Date
- 2019-02-21
- Last Posted Date
- 2022-06-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 344
- Registration Number
- NCT03850483
- Locations
- 🇯🇵
Tanpopo Skin Clinic, Ota Ku, Tokyo, Japan
🇱🇻Aesthetic dermatology clinic of Prof. J. Kisis, Riga, Latvia
🇱🇻Health and Aesthetics Ltd, Riga, Latvia
A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- First Posted Date
- 2019-02-19
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 350
- Registration Number
- NCT03845517
- Locations
- 🇺🇸
Stamford Therapeutics Consortium, Stamford, Connecticut, United States
🇺🇸Institute of Arthritis Research, Idaho Falls, Idaho, United States
🇺🇸Northshore University Hospital, Manhasset, New York, United States